로딩 중…
지수 로딩 중…
BioNote, Inc.
377740· KOSPI· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩4,700+1.08%
2026-11-02
Financials
Valuation Metrics
BioNote, Inc.'s Market Cap is ₩4789B. At end of 2025 it was ₩5573B. Ranked #452 of 2,405 in KR market (top 19%), #290 of 778 on KOSPI (top 37%), #49 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 21%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 478.86B KRW | KR#452/2,405 Sec#49/231 |
| Revenue | 126.41B KRW | KR#1,277/2,405 Sec#78/231 |
| Net Income | -125.69B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 1.56T KRW | KR#363/2,405 Sec#15/231 |
| Net Assets | 1.51T KRW | KR#220/2,405 Sec#9/231 |
| Employees | 313 | KR#767/2,405 Sec#67/231 |
| Value | ||
| P/B | 0.32x | KR#441/2,405 Sec#16/231 |
| P/S | 3.79x | KR#2,082/2,405 Sec#131/231 |
| EV/EBITDA | 22.53x | KR#1,098/2,405 Sec#68/231 |
| FCF Yield | 1.31% | KR#1,116/2,405 Sec#80/231 |
| Profitability | ||
| ROE | -8.32% | KR#1,895/2,405 Sec#140/231 |
| ROA | -8.08% | KR#2,049/2,405 Sec#152/231 |
| Op. Margin | 16.19% | KR#261/2,405 Sec#25/231 |
| Revenue Growth | 12.82% | KR#763/2,405 Sec#74/231 |
| Earnings Growth | -204.60% | KR#1,236/2,405 Sec#84/231 |
| Financial Health | ||
| Debt Ratio | 2.95% | KR#14/2,405 Sec#6/231 |
| Total Debt | 0 KRW | KR—/2,405 Sec—/231 |
| FCF | 6.27B KRW | KR#844/2,405 Sec#57/231 |
| Cash | 17.87B KRW | KR#1,311/2,405 Sec#102/231 |
| Current Ratio | 18.53x | KR#32/2,405 Sec#14/231 |
| Net Debt/EBITDA | -0.87x | KR#407/2,405 Sec#23/231 |
| Dividend | ||
| Div. Yield | 4.82% | KR#340/2,405 Sec#11/231 |
| Div. Growth | 14.00% | KR#532/2,405 Sec#29/231 |
| Performance | ||
| 1Y Return | -14.70% | KR#946/2,405 Sec#57/231 |
| 1M Return | 0.00% | KR#326/2,405 Sec#35/231 |
| From 52W High | -24.92% | KR#296/2,405 Sec#17/231 |
| 1Y MDD | -29.94% | KR#234/2,405 Sec#15/231 |
| Trading | ||
| Volume | 33,829 shares | KR#1,207/2,405 Sec#122/231 |
| Trading Value | 158.9M KRW | KR#1,225/2,405 Sec#139/231 |
| Foreign Own. | 0.54% | KR#2,183/2,405 Sec#210/231 |
| Per Share | ||
| EPS | -1,234 KRW | KR—/2,405 Sec—/231 |
| BPS | 14,833 KRW | KR#707/2,405 Sec#45/231 |
Company Info
Bionote, established in 2003 and listed on the KOSPI market in 2022, specializes in animal diagnostic products and bio-content. Utilizing its unique recombinant antigen and antibody manufacturing technology, it produces and distributes diverse diagnostic products and bio-content across over 80 countries. The company is expanding its business into molecular and biochemical diagnostics. It aims to increase global market share by launching fully automated point-of-care diagnostic devices.